Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
Genes · 2024
DOI: 10.3390/genes15080999 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2024. Verfasst von Umme Sabrina Haque und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Genetic Therapy, Survival of Motor Neuron 1 Protein, Survival of Motor Neuron 2 Protein. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Alberta Faculty of Medicine and Dentistry, the Canadian Institutes of Health Research, the Friends of Garrett Cumming Research Funds, HM Toupin Neurological Science Research Funds, Muscular Dystrophy Canada.
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is a severe genetic disorder characterized by the loss of motor neurons, leading to progressive muscle weakness, loss of mobility, and respiratory complications. In its most severe forms, SMA can result in death within the first two years of life if untreated. The condition arises from mutations in the SMN1 (survival of motor neuron 1) gene, causing a deficiency in the survival motor neuron (SMN) protein. Humans possess a near-identical gene, SMN2, which modifies disease severity and is a primary target for therapies. Recent therapeutic advancements include antisense oligonucleotides (ASOs), small molecules targeting SMN2, and virus-mediated gene replacement therapy delivering a functional copy of SMN1. Additionally, recognizing SMA’s broader phenotype involving multiple organs has led to the development of SMN-independent therapies. Evidence now indicates that SMA affects multiple organ systems, suggesting the need for SMN-independent treatments along with SMN-targeting therapies. No single therapy can cure SMA; thus, combination therapies may be essential for comprehensive treatment. This review addresses the SMA etiology, the role of SMN, and provides an overview of the rapidly evolving therapeutic landscape, highlighting current achievements and future directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
- Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
- The Friends of Garrett Cumming Research & Muscular Dystrophy Canada HM Toupin Neurological Science Research, Edmonton, AB T6G 2H7, Canada.
ORCID-Profile: Toshifumi Yokota
Förderung
- University of Alberta Faculty of Medicine and Dentistry, the Canadian Institutes of Health Research, the Friends of Garrett Cumming Research Funds
- HM Toupin Neurological Science Research Funds
- Muscular Dystrophy Canada
- Women and Children’s Health Research Institute
Zitieren
APA
Haque, U. S., & Yokota, T. (2024). Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges. Genes. https://doi.org/10.3390/genes15080999
Vancouver
Haque US, Yokota T. Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges. Genes. 2024. doi:10.3390/genes15080999
BibTeX
@article{Haque2024,
author = {Haque, Umme Sabrina and Yokota, Toshifumi},
title = {Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15080999}
}
EUVIMED